GC Cell Demonstrates Long-Term Clinical Efficacy of Immuncell-LC Immune Cell Therapy
GC Cell announced on January 30 that the results of a long-term clinical study of its immune cell therapy, Immuncell-LC, for patients with hepatocellular carcinoma have been published in an international academic journal.
This study is notable for integrating the results of approximately nine years of long-term follow-up of participants in a phase 3 randomized controlled trial (RCT) and a large-scale real-world clinical dataset (Real-World Data, RWD) collected from actual medical practice. Through this combined analysis, the study verified the long-term clinical efficacy of Immuncell-LC in reducing the risk of recurrence in patients with hepatocellular carcinoma (liver cancer), who have a high recurrence rate even after curative treatment.
In particular, data evaluating survival effects over such an extended period are extremely rare in the field of immune cell therapy, making these findings significant in clearly demonstrating the long-term clinical value of adjuvant immunotherapy for liver cancer.
In the study, the group receiving immune therapy with Immuncell-LC showed a median recurrence-free survival (mRFS) 14 months longer than the control group after approximately nine years of long-term follow-up in the phase 3 randomized controlled trial. The risk of recurrence was also reduced by 28%. In the overall survival (OS) analysis, the immune therapy group showed a trend toward reduced risk of death compared to the control group. Cancer-specific survival (CSS) was significantly improved in the immune therapy group, with a 51% reduction in cancer-related mortality risk.
Furthermore, in a long-term follow-up analysis based on real-world clinical data from two major domestic medical institutions, the group treated with Immuncell-LC demonstrated a median recurrence-free survival that was extended by 35.5 months compared to the control group, and the risk of recurrence was reduced by 36%.
Professor Lee Junghoon of the Department of Gastroenterology at Seoul National University Hospital, who led the study, stated, "After proving safety and efficacy in the phase 3 clinical trial for liver cancer, we have now confirmed strong evidence for the clinical utility of immune cell therapy as a continuous adjuvant immunotherapy strategy for liver cancer through nine years of long-term follow-up and analysis of real-world data (RWD). Given that even large-scale multinational clinical trials using immune checkpoint inhibitors have recently failed to reduce recurrence in liver cancer, the value of Immuncell-LC in achieving long-term reduction of recurrence is even greater."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
GC Cell CEO Won Sungyong commented, "We are very pleased that the results of this long-term follow-up clinical study have been officially published in a journal. Based on the accumulated clinical evidence in the domestic market, we hope to provide a reliable treatment option for liver cancer patients and healthcare professionals. Furthermore, we will do our utmost to leverage this achievement as we pursue overseas expansion in the future."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.